Compare Sterling Biotech with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs PFIZER - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH PFIZER STERLING BIOTECH/
PFIZER
 
P/E (TTM) x -0.4 33.4 - View Chart
P/BV x 0.0 5.6 0.3% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 STERLING BIOTECH   PFIZER
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
PFIZER
Mar-18
STERLING BIOTECH/
PFIZER
5-Yr Chart
Click to enlarge
High Rs112,365 0.4%   
Low Rs31,625 0.2%   
Sales per share (Unadj.) Rs26.8430.3 6.2%  
Earnings per share (Unadj.) Rs-15.078.7 -19.0%  
Cash flow per share (Unadj.) Rs-5.593.2 -5.9%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs54.9586.5 9.4%  
Shares outstanding (eoy) m267.8745.75 585.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.6 5.6%   
Avg P/E ratio x-0.525.3 -1.8%  
P/CF ratio (eoy) x-1.321.4 -5.9%  
Price / Book Value ratio x0.13.4 3.7%  
Dividend payout %025.4 0.0%   
Avg Mkt Cap Rs m1,86291,271 2.0%   
No. of employees `0001.42.6 51.5%   
Total wages/salary Rs m5473,143 17.4%   
Avg. sales/employee Rs Th5,303.37,484.8 70.9%   
Avg. wages/employee Rs Th403.81,195.0 33.8%   
Avg. net profit/employee Rs Th-2,959.01,369.1 -216.1%   
INCOME DATA
Net Sales Rs m7,18119,685 36.5%  
Other income Rs m431,143 3.7%   
Total revenues Rs m7,22320,828 34.7%   
Gross profit Rs m9475,003 18.9%  
Depreciation Rs m2,543663 383.9%   
Interest Rs m4,3774 104,216.7%   
Profit before tax Rs m-5,9315,479 -108.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9241,878 -102.4%   
Profit after tax Rs m-4,0073,601 -111.3%  
Gross profit margin %13.225.4 51.9%  
Effective tax rate %32.434.3 94.6%   
Net profit margin %-55.818.3 -305.0%  
BALANCE SHEET DATA
Current assets Rs m14,33524,167 59.3%   
Current liabilities Rs m49,8099,544 521.9%   
Net working cap to sales %-494.074.3 -665.0%  
Current ratio x0.32.5 11.4%  
Inventory Days Days40355 732.3%  
Debtors Days Days17129 594.5%  
Net fixed assets Rs m55,4329,514 582.7%   
Share capital Rs m268458 58.6%   
"Free" reserves Rs m13,93526,375 52.8%   
Net worth Rs m14,70126,832 54.8%   
Long term debt Rs m9,47825 37,911.4%   
Total assets Rs m73,98836,900 200.5%  
Interest coverage x-0.41,305.5 -0.0%   
Debt to equity ratio x0.60 69,194.1%  
Sales to assets ratio x0.10.5 18.2%   
Return on assets %0.59.8 5.1%  
Return on equity %-27.313.4 -203.1%  
Return on capital %-6.420.4 -31.5%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86022 8,302.7%   
Fx outflow Rs m251,489 1.7%   
Net fx Rs m1,835-1,466 -125.1%   
CASH FLOW
From Operations Rs m1,7193,318 51.8%  
From Investments Rs m-3,148-2,383 132.1%  
From Financial Activity Rs m1,426-1,104 -129.2%  
Net Cashflow Rs m-3-169 2.0%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 0.0 7.5 -  
FIIs % 9.9 4.9 202.0%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 23.7 165.8%  
Shareholders   21,482 85,207 25.2%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON   

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS